These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31837382)

  • 1. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
    de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
    Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.
    de Vries RD; Nieuwkoop NJ; van der Klis FRM; Koopmans MPG; Krammer F; Rimmelzwaan GF
    J Infect Dis; 2017 Dec; 217(1):3-11. PubMed ID: 29294018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.
    de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF
    Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADCC: An underappreciated correlate of cross-protection against influenza?
    de Vries RD; Hoschler K; Rimmelzwaan GF
    Front Immunol; 2023; 14():1130725. PubMed ID: 36911705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.
    Jegaskanda S; Amarasena TH; Laurie KL; Tan HX; Butler J; Parsons MS; Alcantara S; Petravic J; Davenport MP; Hurt AC; Reading PC; Kent SJ
    J Virol; 2013 Dec; 87(24):13706-18. PubMed ID: 24109221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
    Florek K; Mutschler J; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
    Vaccine; 2020 Feb; 38(8):2088-2094. PubMed ID: 31753674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
    Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.
    Nakajima R; Supnet M; Jasinskas A; Jain A; Taghavian O; Obiero J; Milton DK; Chen WH; Grantham M; Webby R; Krammer F; Carter D; Felgner PL; Davies DH
    mSphere; 2018 Dec; 3(6):. PubMed ID: 30541779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
    Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an Alternative Modified Live Influenza B Virus Vaccine.
    Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.